Guideline for the treatment and prophylaxis of Ifosfamide induced Encephalitis.

Ifosfamide is an alkylating agent used to treat a range of solid and haematological malignancies. Its use can lead to central nervous system (CNS) toxicity in 10-30% (mean 12%) of patients after intravenous administration.

The onset of symptoms occurs between 12 and 146 hours after the start of administration. CNS toxicity is increased by 50% with oral administration due to differences in metabolism between the two routes. Methylthioninium chloride (Proveblue®) is not licensed for the treatment of ifosfamide induced encephalopathy (IIE), so its use is off-label. Its mechanism of action is unclear, it is proposed that its activity as an electron acceptor reduces the formation of the toxic metabolite chloroacetaldehyde.

Printable version of this page

Methylthioninium Chloride (Proveblue®) Department: Pharmacy PDF, 353.2 KB, 3 pages